---
title: "Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Diagnosis"
description: "Formulary evidence on Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Diagnosis. Topics: EAN/PNS 2021 guideline: two levels of diagnostic certainty and supportive criteria, Diagnostic accuracy of the EAN/PNS 2021 criteria compared with the EFNS/PNS 2010 criteria, Misdiagnosis in the United States: referred patients who did not meet diagnostic criteria, Overdiagnosis and underdiagnosis at a European referral center, and 1 further topic. 5 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description/diagnosis"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Diagnosis

<a id="heading-2.2.1.5"></a>

## 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

### EAN/PNS 2021 guideline: two levels of diagnostic certainty and supportive criteria

> “The levels of diagnostic certainty were reduced from three (definite, probable, possible CIDP) to only two (CIDP and possible CIDP), because the diagnostic accuracy of criteria for probable and definite CIDP did not significantly differ. Good Practice Points were formulated for supportive criteria and investigations to be considered to diagnose CIDP.”

Source: [Van den Bergh et al. (2021)](https://onlinelibrary.wiley.com/doi/10.1111/ene.14959)

> “Some notable changes from the previous guideline include the removal of distinctions between “definite” and “probable” conduction blocks, consolidating them into a singular category of conduction blocks. Furthermore, tibial nerve conduction blocks are no longer included and the threshold for temporal dispersion in the tibial nerve has been adjusted to necessitate at least a 100% increase in CMAP duration. Sensory criteria have transitioned from being merely supportive to being integral to the electrodiagnostic criteria.”

Source: [van Doorn et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10875175/)

<a id="topic-2.2.1.5-2"></a>

### Diagnostic accuracy of the EAN/PNS 2021 criteria compared with the EFNS/PNS 2010 criteria

> “We included 339 patients and 339 matched controls. Sensitivity of the 2010 EFNS/PNS guideline was 92% when including possible CIDP and 91% for probable/definite CIDP, with specificities of 67% and 78%, respectively. For the 2021 EAN/PNS guideline, sensitivity was 94% when including possible CIDP and 83% for CIDP, with specificities of 66% and 86%, respectively. Differences were due to sensory criteria and changes in conduction block criteria. Unilateral NCS would miss 77 possible CIDP diagnoses.”

Source: [van Doorn et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13434837/)

<a id="topic-2.2.1.5-3"></a>

### Misdiagnosis in the United States: referred patients who did not meet diagnostic criteria

> “Forty-seven percent of patients referred with a diagnosis of CIDP failed to meet minimal CIDP diagnostic requirements.”
> “CIDP misdiagnosis is common. Over-reliance on subjective patient-reported perception of treatment benefit, liberal electrophysiologic interpretation of demyelination, and placing an overstated importance on mild or moderate cytoalbuminologic dissociation are common diagnostic errors.”

Source: [Allen and Lewis (2015)](https://pubmed.ncbi.nlm.nih.gov/26180143/)

> “Thirty-nine of 86 patients were found not to have CIDP. Initial electrodiagnostic data quality was generally acceptable, but initial electrodiagnostic conclusions were confirmed in only 45% of misdiagnosed studies.”

Source: [Allen et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29053880/)

<a id="topic-2.2.1.5-4"></a>

### Overdiagnosis and underdiagnosis at a European referral center

> “A referral diagnosis of CIDP was revised in 32% of patients (31/96; overdiagnosis). Of 81 patients diagnosed with CIDP, 16 (20%) were referred with another diagnosis (underdiagnosis).”
> “Diagnostic pitfalls include lack of attention to proximal muscle weakness as a diagnostic hallmark of CIDP, insufficient recognition of clinical atypical phenotypes, overreliance on CSF protein levels, misinterpretation of nerve conduction studies and poor adherence to electrodiagnostic criteria, and failure to exclude other causes of polyneuropathy.”

Source: [Broers et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8252611/)

<a id="topic-2.2.1.5-5"></a>

### Initial misdiagnosis and diagnostic delay in a multinational survey

> “Overall, initial misdiagnosis occurred in 37.2% of patients, with a median (interquartile range) diagnostic delay of 6.0 (3.0–12.0) months.”

Source: [Querol et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12361836/)

## Related pages
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: References](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references.md)
